Climb Bio SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 26, 2026, 6:24 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedClimb Bio (CLYM) Reports Initial PrisMN Phase 2 Budoprutug Data in pMN: 70% Mean PLA2R Reduction and 38% Immunologic Remission at Week 12 in 200 mg Cohort
8-KOct. 23, 2026, 5:26 p.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedClimb Bio Reports Additional CLYM116 Phase 1 Data: ~33-Day Half-Life and ~70% Gd-IgA1 Reduction at 12 Weeks
8-KSept. 3, 2026, 7:50 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KAug. 14, 2026, 8:30 a.m. ETView on SEC.gov
Other events
8-KAug. 6, 2026, 7:35 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits